Terms: = Prostate cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Diagnosis
31 results:
1. Family History of prostate cancer and Survival Outcomes in the UK Genetic prostate cancer Study.
Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
[TBL] [Abstract] [Full Text] [Related]
2. Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
Sasaki T; Matsumoto R; Higashi S; Kato M; Masui S; Yoshio Y; Nishikawa K; Inoue T
Int J Urol; 2022 Nov; 29(11):1339-1346. PubMed ID: 36000706
[TBL] [Abstract] [Full Text] [Related]
3. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
[TBL] [Abstract] [Full Text] [Related]
4. Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
Campbell KJ; Leung HY
Cancer Lett; 2021 Nov; 520():213-221. PubMed ID: 34343635
[TBL] [Abstract] [Full Text] [Related]
5. Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
Sandahl M; Pedersen BG; Ulhøi BP; Borre M; Sørensen KD
BJU Int; 2021 Dec; 128(6):702-712. PubMed ID: 33964113
[TBL] [Abstract] [Full Text] [Related]
6. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
[TBL] [Abstract] [Full Text] [Related]
7. The association between family history of prostate cancer and development of prostate cancer among Korean population: A prospective cohort study using KoGES data.
Choi HG; Bang WJ; Jo JK; Oh CY; Shim M; Cho JS
Medicine (Baltimore); 2021 Feb; 100(7):e24757. PubMed ID: 33607822
[TBL] [Abstract] [Full Text] [Related]
8. Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men;results from an equal access biopsy study.
Jenkins KR; Oyekunle T; Howard LE; Wiggins EK; Freedland SJ; Allott EH
Cancer Causes Control; 2021 Apr; 32(4):337-346. PubMed ID: 33532986
[TBL] [Abstract] [Full Text] [Related]
9. Performance of Three Inherited Risk Measures for Predicting prostate cancer Incidence and Mortality: A Population-based Prospective Analysis.
Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
[TBL] [Abstract] [Full Text] [Related]
10. Synthesis and evaluation of a UMI-77-based fluorescent probe for selective detecting mcl-1 protein and imaging in living cancer cells.
Li J; Hou X; Bai J; Zhou Y; Chen C; Yang X; Fang H
Bioorg Med Chem; 2021 Jan; 29():115850. PubMed ID: 33229135
[TBL] [Abstract] [Full Text] [Related]
11. Patterns of cancer family history and genetic counseling eligibility among African Americans with breast, prostate, lung, and colorectal cancers: A Detroit Research on cancer Survivors cohort study.
Purrington KS; Schwartz AG; Ruterbusch JJ; Manning MA; Nair M; Wenzlaff AS; Pandolfi SS; Simon MS; Beebe-Dimmer J
Cancer; 2020 Nov; 126(21):4744-4752. PubMed ID: 32749684
[TBL] [Abstract] [Full Text] [Related]
12. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at prostate cancer diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract] [Full Text] [Related]
13. Transition zone prostate cancer: Logistic regression and machine-learning models of quantitative ADC, shape and texture features are highly accurate for diagnosis.
Wu M; Krishna S; Thornhill RE; Flood TA; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Sep; 50(3):940-950. PubMed ID: 30701625
[TBL] [Abstract] [Full Text] [Related]
14. Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
Thalgott M; Kron M; Brath JM; Ankerst DP; Thompson IM; Gschwend JE; Herkommer K
World J Urol; 2018 Feb; 36(2):177-185. PubMed ID: 29164326
[TBL] [Abstract] [Full Text] [Related]
15. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract] [Full Text] [Related]
16. Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT; Kearns J; Conran C; Xu J
Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
[TBL] [Abstract] [Full Text] [Related]
17. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract] [Full Text] [Related]
18. External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
Greene DJ; Elshafei A; Nyame YA; Kara O; Malkoc E; Gao T; Jones JS
Prostate; 2016 Aug; 76(11):1019-23. PubMed ID: 27197726
[TBL] [Abstract] [Full Text] [Related]
19. Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy.
Westerman ME; Gershman B; Karnes RJ; Thompson RH; Rangel L; Boorjian SA
World J Urol; 2016 Aug; 34(8):1115-22. PubMed ID: 26658661
[TBL] [Abstract] [Full Text] [Related]
20. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract] [Full Text] [Related]
[Next]
